Wegovy(r) receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

Source :: Plus Company Updates. March 11, 2024
Publication Year :: 2024
Abstract: PLAINSBORO, N.J: Novo Nordisk has issued the following news release: Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy(r) to [...]

Subjects :: United States. Food and Drug Administration
Heart attack -- Drug therapy -- Risk factors
Obesity -- Drug therapy -- Risk factors
Drug approval
Adults
General interest
News, opinion and commentary
Wegovy (Medication)

Tools